Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII

Molecular Therapy

Volumn 3, Issue 3, 2001, Pages 329-336

  Andrews, Julie L ^a   Kadan, Michael J ^a   Gorziglia, Mario I ^a   Kaleko, Michael ^a   Connelly, Sheila ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BLOOD CLOTTING FACTOR 8; LIVER ENZYME; VIRUS PROTEIN; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GENE CASSETTE; GENE DELETION; GENE EXPRESSION; GENE THERAPY; GENETIC CODE; GENETIC TRANSDUCTION; HEMOPHILIA; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LIVER; LIVER TOXICITY; MOUSE; NONHUMAN; OPEN READING FRAME; PROMOTER REGION; PROTEIN EXPRESSION; TOXICITY; TRANSGENE; VIRUS ATTENUATION; VIRUS GENE;

ADENOVIRIDAE; ANIMALIA;

EID: 0034986027     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2001.0264     Document Type: Article

References (59)

1. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy
2. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses
3. Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo
4. Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduce cells in mouse lungs
5. Adenovirus-mediated gene transfer: Influence of transgene, mouse strain and type of immune response on persistence of transgene expression
6. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors
7. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: Comparisons between immunocompetent and immunodeficient inbred strains
8. Effect of the E4 region on the persistence of transgene expression from adenovirus vectors
9. Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo
10. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenovirus
11. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: Comparison of E2a wild type and E2a deleted vectors
12. Sustained expression of therapeutic levels of human factor VIII in mice
13. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy
14. Adenovirus-mediated expression of therapeutic plasma levels of human factor IX in mice
15. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis
16. Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha1-antitrypsin after systemic delivery
17. Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses
18. Adenoviral vector-mediated expression of physiologic levels of human factor VIII in nonhuman primates
19. Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products
20. Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs
21. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons
22. High-capacity adenoviral vectors for gene transfer and somatic gene therapy
23. Optimization of the helper-dependent adenovirus system for production and potency in vivo
24. Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector
25. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector
26. Adenoviral vectors
27. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted
28. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver
29. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy
30. Elimination of both E1 and E2a from adenovirus vectors further improves prospects for in vivo human gene therapy
31. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted
32. Persistent transgene expression in mouse liver following in vivo gene transfer with a deltaE1/deltaE4 adenovirus vector
33. Generation of an adenovirus vector lacking E1, E2a, E3, and all of E4 except open reading frame 3
34. Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: Requirement for E4 ORF3
35. Redundant control of adenovirus late gene expression by early region 4
36. Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1
37. High level tissue-specific expression of functional human FVIII in mice
38. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy
39. In vivo evaluation of a novel epitope-tagged human factor VIII-encoding adenoviral vector
40. In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice
41. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A
42. The mouse
43. E4ORF3 requirement for achieving long-term transgene expression from the cytomegalovirus promoter in adenovirus vectors
44. Evaluation of an adenoviral vector encoding full-length factor VIII in hemophiliac mice
45. In vivo evaluation of an adenoviral vector encoding canine factor VIII: High-level, sustained expression in hemophiliac mice
46. Virus-vs endotoxin-induced activation of liver macrophages
47. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia
48. Regulation of TNF-mediated cell death and inflammation by human adenoviruses
49. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors
50. Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion
51. NF-kappa B activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T cell stimulation
52. Factors influencing physiological variations in the activity of the Rous sarcoma virus long terminal repeat
53. E4 gene function in adenovirus, adenovirus vector and adeno-associated virus infections
54. Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor
55. Adenovirus E4orf4 protein binds to protein phosphatase 2A, and the complex down regulates E1A-enhanced junB transcription
56. The adenovirus E4orf6 protein can promote E1A/E1B-induced focus formation by interfering with p53 tumor suppressor function
57. Utilization of cellular transcription factors for adenovirus-induced transcription
58. Targeting of adenovirus E1A and E4-ORF3 proteins to nuclear matrix-associated PML bodies
59. Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure